Search - tctmd.com

Displaying 241 - 260 of 677

Sort: Relevancy | Date

Podcast Rox Heart Radio

LBTs at TCT 2018 - How Will These LBTs Change My Practice?

January 24, 2019

Podcast TCTMD Talking Points

Women in Innovation

December 19, 2018

Podcast TCTMD Talking Points

Stent Wars

December 05, 2018

News Conference News AHA 2018

Cell Therapy No Help for Cardiac Recovery in HF Patients With LVADs

Yael L. Maxwell

November 12, 2018

News Daily News

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Caitlin E. Cox

October 31, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Presentation TCT 2018

Diversity in the Interventional Workplace: Current Challenges and Opportunities

Presenter: Wayne B. Batchelor, Aaron Horne, Jr., Roxana Mehran

September 24, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Presenter: Peter Juni, Robert W. Yeh, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Case #2 Conclusion: How Did I Actually Treat This Patient?

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Case #2 Introduction: A Patient With Chronic CAD At High Bleeding Risk Requiring PCI

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Case #1 Conclusion: How Did I Actually Treat This Patient?

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

Presentation TCT 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

Topic 5: CIN Prevention Strategies

Presenter: Sripal Bangalore, Somjot S. Brar, Roxana Mehran

September 23, 2018

Advertisement

LBTs at TCT 2018 - How Will These LBTs Change My Practice?

Women in Innovation

Stent Wars

Cell Therapy No Help for Cardiac Recovery in HF Patients With LVADs

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Diversity in the Interventional Workplace: Current Challenges and Opportunities

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Case #2 Conclusion: How Did I Actually Treat This Patient?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Case #2 Introduction: A Patient With Chronic CAD At High Bleeding Risk Requiring PCI

Case #1 Conclusion: How Did I Actually Treat This Patient?

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

Patient Perspectives on Sham-Controlled Trials

FDA Perspectives on Sham-Controlled Trials

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

ORBITA One Year Later: What Would I Do Differently, If Anything?

Topic 5: CIN Prevention Strategies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content